Interleukin (IL)-13 as a Marker in Pediatrics Asthma

Cytokine Production in Children With Asthma.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00968305

Enrollment

Registered

2009-08-28

Start date

2008-11-30

Completion date

2009-08-31

Last updated

2009-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

African American children with stable asthma, Asthma severity, Interleukin 13 from PHA stimulated PBMC, Lung function (FEV1%), Total serum IgE, Pediatrics

Brief summary

Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.

Detailed description

This study examined the relationship between Interleukin (IL)-13 from phytohemagglutinin-activated polymorphonuclear blood cells and asthma severity, lung function (measured as FEV1%), and total serum IgE levels in African American children with clinically diagnosed asthma

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

8 Years to 15 Years

Healthy volunteers

Inclusion criteria

* African-American race, born in the U.S. * Age 8-15 years * Clinical diagnosis of asthma * Subject is able to understand and follow verbal instructions in English

Exclusion criteria

* Asthma exacerbation in the 4 weeks preceding the research visit * Oral/IV steroid use in the 4 weeks preceding the research visit * Upper or lower respiratory tract infection in the 4 weeks preceding the research visit * Antibiotic use in the 4 weeks preceding the research visit * Use of a short-acting bronchodilator during the 6 hours prior to spirometry (lung function testing) * Use of a long-acting bronchodilator during the 12 hours prior to spirometry (lung function testing)

Design outcomes

Primary

Measure	Time frame
Interleukin-13 from phytohemagglutinin activated peripheral blood mononuclear cells	7 months (from the start to completion of study. The blood was drawn at the one and only visit for each subject)

Secondary

Measure	Time frame
Lung function measured by percent predicted forced expiratory volume in the first second (FEV1%)	7 months (from the start to completion of study, but FEV1% was measured at the one and only visit for each subject)

Countries

United States

Outcome results